Keywords: wyeth, 4th-qtr, income, climbs, shy, estimates, predicts
Wyeth's 4th-qtr 2007 income climbs 18% just shy of estimates; predicts flat 2008 on generic competition
Article | 11 February 2008
USA-based drugmaker Wyeth reported adjusted income of $1.06 billion, or $0.78 per share, for the three months ended December 31, 2007, up 17.7% on its ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
